| Nome |
# |
|
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy, file e0d6c92d-ba10-fcf8-e053-d805fe0aa794
|
878
|
|
Sunitinib in the treatment of thyroid cancer, file e0d6c92c-8edc-fcf8-e053-d805fe0aa794
|
863
|
|
Myo-inositol in autoimmune thyroiditis, and hypothyroidism, file e0d6c92c-c344-fcf8-e053-d805fe0aa794
|
401
|
|
New insight in endocrine-related adverse events associated to immune checkpoint blockade, file e0d6c92e-5ace-fcf8-e053-d805fe0aa794
|
268
|
|
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy, file e0d6c92f-5e13-fcf8-e053-d805fe0aa794
|
263
|
|
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series, file e0d6c92c-8a37-fcf8-e053-d805fe0aa794
|
252
|
|
The protective effect of myo-inositol on human thyrocytes, file e0d6c92c-629b-fcf8-e053-d805fe0aa794
|
224
|
|
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses, file e0d6c92f-3a04-fcf8-e053-d805fe0aa794
|
209
|
|
Molecular testing in the diagnosis of differentiated thyroid carcinomas, file e0d6c92b-0496-fcf8-e053-d805fe0aa794
|
155
|
|
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update, file e0d6c92d-47ed-fcf8-e053-d805fe0aa794
|
122
|
|
Novel therapies for thyroid autoimmune diseases: An update, file e0d6c92d-ba0e-fcf8-e053-d805fe0aa794
|
119
|
|
Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide, file e0d6c92a-e2a5-fcf8-e053-d805fe0aa794
|
118
|
|
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study, file e0d6c92b-6080-fcf8-e053-d805fe0aa794
|
109
|
|
Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells, file e0d6c92a-bd40-fcf8-e053-d805fe0aa794
|
107
|
|
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo, file e0d6c92a-c610-fcf8-e053-d805fe0aa794
|
106
|
|
Autoimmune endocrine dysfunctions associated with cancer immunotherapies, file e0d6c92d-536f-fcf8-e053-d805fe0aa794
|
82
|
|
Evaluating vandetanib in the treatment of medullary thyroid cancer: Patient-reported outcomes, file e0d6c92d-c6ee-fcf8-e053-d805fe0aa794
|
81
|
|
Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells, file e0d6c92a-a291-fcf8-e053-d805fe0aa794
|
79
|
|
Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C?, file e0d6c92e-1304-fcf8-e053-d805fe0aa794
|
76
|
|
CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide, file e0d6c92a-8ae7-fcf8-e053-d805fe0aa794
|
75
|
|
Chemokines in hyperthyroidism, file e0d6c92d-4ced-fcf8-e053-d805fe0aa794
|
75
|
|
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo, file e0d6c92a-e9af-fcf8-e053-d805fe0aa794
|
72
|
|
null, file e0d6c929-7733-fcf8-e053-d805fe0aa794
|
70
|
|
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration, file e0d6c92b-c429-fcf8-e053-d805fe0aa794
|
65
|
|
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases, file e0d6c92e-9473-fcf8-e053-d805fe0aa794
|
65
|
|
Immune and inflammatory cells in thyroid cancer microenvironment, file e0d6c92d-f93c-fcf8-e053-d805fe0aa794
|
63
|
|
Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis, file e0d6c92c-9443-fcf8-e053-d805fe0aa794
|
51
|
|
Endocrine disruptors and thyroid autoimmunity, file e0d6c92f-4f2b-fcf8-e053-d805fe0aa794
|
43
|
|
Novel treatment options for anaplastic thyroid cancer, file e0d6c92c-bbab-fcf8-e053-d805fe0aa794
|
41
|
|
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy, file e0d6c92d-6599-fcf8-e053-d805fe0aa794
|
40
|
|
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy, file e0d6c92d-ba03-fcf8-e053-d805fe0aa794
|
40
|
|
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin, file e0d6c931-b237-fcf8-e053-d805fe0aa794
|
38
|
|
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments, file e0d6c932-2dae-fcf8-e053-d805fe0aa794
|
31
|
|
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study, file e0d6c92c-a58d-fcf8-e053-d805fe0aa794
|
22
|
|
Th1 chemokines in autoimmune endocrine disorders, file e0d6c92e-3dd1-fcf8-e053-d805fe0aa794
|
20
|
|
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy, file e0d6c931-5f3c-fcf8-e053-d805fe0aa794
|
19
|
|
Chemokines in hyperthyroidism, file e0d6c92d-a49d-fcf8-e053-d805fe0aa794
|
13
|
|
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses, file e0d6c92f-3a03-fcf8-e053-d805fe0aa794
|
12
|
|
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors, file e0d6c92f-4fc3-fcf8-e053-d805fe0aa794
|
9
|
|
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases, file e0d6c931-46d4-fcf8-e053-d805fe0aa794
|
5
|
|
Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis, file e0d6c929-87fd-fcf8-e053-d805fe0aa794
|
4
|
|
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update, file e0d6c92d-4e50-fcf8-e053-d805fe0aa794
|
4
|
|
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin, file e0d6c92f-0fbf-fcf8-e053-d805fe0aa794
|
4
|
|
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series, file e0d6c92b-c61c-fcf8-e053-d805fe0aa794
|
3
|
|
Recent advances in precision medicine for the treatment of anaplastic thyroid cancer, file e0d6c92d-4cf3-fcf8-e053-d805fe0aa794
|
2
|
|
Novel therapies for thyroid autoimmune diseases: An update, file e0d6c92d-cbf0-fcf8-e053-d805fe0aa794
|
2
|
|
New insight in endocrine-related adverse events associated to immune checkpoint blockade, file e0d6c92f-267a-fcf8-e053-d805fe0aa794
|
2
|
|
Th1 chemokines in autoimmune endocrine disorders, file e0d6c92f-4f13-fcf8-e053-d805fe0aa794
|
2
|
|
Nutraceuticals in thyroidology: A review of in vitro, and in vivo animal studies, file e0d6c92f-6431-fcf8-e053-d805fe0aa794
|
2
|
|
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy, file e0d6c92f-6438-fcf8-e053-d805fe0aa794
|
2
|
|
Novel treatment options for anaplastic thyroid cancer, file e0d6c929-c09c-fcf8-e053-d805fe0aa794
|
1
|
|
Myo-inositol in autoimmune thyroiditis, and hypothyroidism, file e0d6c92b-8b3e-fcf8-e053-d805fe0aa794
|
1
|
|
The protective effect of myo-inositol on human thyrocytes, file e0d6c92b-dc81-fcf8-e053-d805fe0aa794
|
1
|
|
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy, file e0d6c92d-af62-fcf8-e053-d805fe0aa794
|
1
|
|
Novel treatments for anaplastic thyroid carcinoma, file e0d6c92e-425f-fcf8-e053-d805fe0aa794
|
1
|
|
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases, file e0d6c92e-8205-fcf8-e053-d805fe0aa794
|
1
|
|
Endocrine disruptors and thyroid autoimmunity, file e0d6c92f-3288-fcf8-e053-d805fe0aa794
|
1
|
|
null, file e0d6c931-4d9a-fcf8-e053-d805fe0aa794
|
1
|
|
Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies, file e0d6c932-2879-fcf8-e053-d805fe0aa794
|
1
|
| Totale |
5.417 |